Hologic, Inc. (NASDAQ:HOLX) – Research analysts at William Blair cut their Q1 2020 earnings estimates for shares of Hologic in a note issued to investors on Wednesday, November 20th. William Blair analyst B. Weinstein now forecasts that the medical equipment provider will post earnings of $0.61 per share for the quarter, down from their prior estimate of $0.64. William Blair also issued estimates for Hologic’s Q3 2020 earnings at $0.67 EPS and FY2020 earnings at $2.61 EPS.

Several other equities analysts have also recently commented on HOLX. Needham & Company LLC reaffirmed a “buy” rating and set a $57.00 price objective (up previously from $52.00) on shares of Hologic in a research note on Thursday, August 1st. BidaskClub cut shares of Hologic from a “hold” rating to a “sell” rating in a research note on Thursday, November 7th. Argus boosted their price objective on shares of Hologic to $62.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. BTIG Research reaffirmed a “buy” rating and set a $52.00 price objective on shares of Hologic in a research note on Thursday, August 1st. Finally, Zacks Investment Research raised shares of Hologic from a “hold” rating to a “buy” rating and set a $54.00 price objective for the company in a research note on Friday, August 16th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $51.19.

HOLX opened at $49.19 on Thursday. The firm has a 50-day moving average price of $48.24 and a 200-day moving average price of $48.11. The company has a market capitalization of $12.60 billion, a price-to-earnings ratio of 20.24, a PEG ratio of 2.06 and a beta of 0.76. Hologic has a twelve month low of $37.48 and a twelve month high of $52.19. The company has a quick ratio of 1.26, a current ratio of 1.68 and a debt-to-equity ratio of 1.22.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, November 6th. The medical equipment provider reported $0.65 earnings per share for the quarter, hitting the consensus estimate of $0.65. The firm had revenue of $865.80 million during the quarter, compared to the consensus estimate of $846.54 million. Hologic had a negative net margin of 1.19% and a positive return on equity of 29.14%. The company’s revenue was up 6.4% on a year-over-year basis. During the same quarter last year, the company earned $0.58 earnings per share.

Several institutional investors and hedge funds have recently made changes to their positions in HOLX. CWM LLC raised its holdings in Hologic by 3,466.7% during the 2nd quarter. CWM LLC now owns 535 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 520 shares during the last quarter. Horan Capital Advisors LLC. purchased a new stake in Hologic during the 3rd quarter valued at approximately $34,000. CSat Investment Advisory L.P. grew its holdings in Hologic by 66.9% during the 2nd quarter. CSat Investment Advisory L.P. now owns 831 shares of the medical equipment provider’s stock valued at $40,000 after buying an additional 333 shares in the last quarter. SevenBridge Financial Group LLC grew its holdings in Hologic by 172.0% during the 2nd quarter. SevenBridge Financial Group LLC now owns 1,205 shares of the medical equipment provider’s stock valued at $58,000 after buying an additional 762 shares in the last quarter. Finally, North Star Investment Management Corp. purchased a new stake in Hologic during the 3rd quarter valued at approximately $80,000. Hedge funds and other institutional investors own 96.98% of the company’s stock.

In other news, CEO Stephen P. Macmillan sold 194,396 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $45.91, for a total value of $8,924,720.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Peter J. Valenti III sold 7,766 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $49.14, for a total transaction of $381,621.24. The disclosure for this sale can be found here. Insiders own 0.90% of the company’s stock.

About Hologic

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Read More: What is a good rate of return for a mutual fund?

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.